New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:14 EDTEXASExact Sciences announces FDA approved Cologuard
Exact Sciences announced that the FDA has approved Cologuard, the company's noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
15:49 EDTEXASExact Sciences says CMS advisors vote to maintain Cologuard reimbursement rate
Subscribe for More Information
August 24, 2015
08:00 EDTEXASExact Sciences price target lowered to $26 from $32 at Canaccord
Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use